A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs ARGX 110 (Primary)
- Indications Cancer; Cutaneous T cell lymphoma; Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors argenx
- 25 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2017 According to an argenx media release, interim results will be presented during a workshop being held in conjunction with the American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2017 .
- 11 Dec 2017 Interim results (n=22) presented in an argenx Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History